These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1606075)

  • 21. TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    Van Oosterom AT; Droz JP; Fossa ST; Bono AV; Splinter TA; Verbaeys AJ; Keizer J; De Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1889-90. PubMed ID: 2632270
    [No Abstract]   [Full Text] [Related]  

  • 22. Metastatic renal cancer: better never than late.
    Galsky MD
    Eur Urol; 2014 Jun; 65(6):1093-4. PubMed ID: 23954087
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase II study of navelbine in advanced renal cell carcinoma.
    Canobbio L; Boccardo F; Guarneri D; Calabria C; Decensi A; Curotto A; Martorana G; Giuliani L
    Eur J Cancer; 1991; 27(6):804-5. PubMed ID: 1829928
    [No Abstract]   [Full Text] [Related]  

  • 24. Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    van Oosterom AT; Fosså SD; Pizzocaro G; Bergerat JP; Bono AV; De Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1239-41. PubMed ID: 6541582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib rechalenge in metastatic renal cell carcinoma.
    Porta C; Paglino C; Imarisio I
    BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase II trial of methyl-gag and melphalan in metastatic adult renal cell carcinoma.
    Guimaraes JL; Ghosn M; Ostronoff M; Azab M; Theodore C; Droz JP
    Cancer Invest; 1990; 8(6):623-4. PubMed ID: 2292054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].
    Rexer H
    Urologe A; 2015 Oct; 54(10):1443-5. PubMed ID: 26350358
    [No Abstract]   [Full Text] [Related]  

  • 28. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.
    Taylor CW; Alberts DS; Peng YM; McCloskey TM; Matzner M; Roe DJ; Plezia PM; Grindey GB; Hamilton M; Seitz D
    J Natl Cancer Inst; 1992 Dec; 84(23):1798-802. PubMed ID: 1433369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal.
    Barata PC; Alpuim Costa D; Passos Coelho JL; Da Luz R
    Acta Med Port; 2018 Aug; 31(7-8):373-375. PubMed ID: 30189164
    [No Abstract]   [Full Text] [Related]  

  • 30. Intermittent sunitinib for metastatic renal cell carcinoma.
    Venkatesan P
    Lancet Oncol; 2017 Mar; 18(3):e139. PubMed ID: 28163004
    [No Abstract]   [Full Text] [Related]  

  • 31. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma.
    Van Poppel H
    Eur Urol; 2008 Aug; 54(2):324. PubMed ID: 18485572
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma.
    Ficarra V; Novara G
    Eur Urol; 2008 Aug; 54(2):324-5. PubMed ID: 18485580
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program.
    Sternberg CN; Yagoda A; Scher H; Bosl G; Dershaw D; Rosado K; Houston C; Rosenbluth R; Vinciguerra V; Boselli B
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):753-4. PubMed ID: 2523810
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma.
    Trump DL; Elson P
    Invest New Drugs; 1990 May; 8(2):201-3. PubMed ID: 2200758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New perspectives in the treatment of metastatic renal cell carcinoma.
    Barrière J; Hoch B; Ferrero JM
    Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e16-23. PubMed ID: 22099727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
    Patel PH; Kondagunta GV; Schwartz L; Ishill N; Bacik J; DeLuca J; Russo P; Motzer RJ
    Invest New Drugs; 2008 Jun; 26(3):273-6. PubMed ID: 18161005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression-free survival as endpoint in metastatic RCC?
    Knox JJ
    Lancet; 2008 Aug; 372(9637):427-9. PubMed ID: 18653227
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma.
    Vuky J; Isacson C; Fotoohi M; dela Cruz J; Otero H; Picozzi V; Malpass T; Aboulafia D; Jacobs A
    Invest New Drugs; 2006 Jan; 24(1):85-8. PubMed ID: 16380835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
    Carver BS
    J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983-1988.
    Yagoda A
    Prog Clin Biol Res; 1990; 350():227-41. PubMed ID: 2201045
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.